Globus Medical expects the Nevro acquisition to be accretive to its earnings in the second year of operation. Globus Medical expects to report full financial results for 2024 and provide its updated ...

innovative products that significantly reduce the burden of chronic pain,” said Kevin Thornal, Nevro’s CEO and President. “Through Globus Medical’s capabilities, global infrastructure and ...

Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 results, is ...

Nevro (NYSE:NVRO – Get Free Report) was upgraded by research analysts at Jefferies Financial Group from an “underperform” rating to a “hold” rating in a research note issued to investors on Monday, ...

Globus Medical (NYSE:GMED) said it has agreed to buy Nevro (NVRO) through an all-cash deal with an equity value of around $250M. Under the deal, Globus Medical (NYSE:GMED) will buy all of Nevro's ...

subject to the approval of Nevro’s shareholders and regulatory approval. Globus specializes in developing and manufacturing orthopedic implants and regenerative products for musculoskeletal ...

innovative products that significantly reduce the burden of chronic pain,” said Kevin Thornal, Nevro's CEO and President.“Through Globus Medical's capabilities, global infrastructure and other ...